Argatroban

Journal of Thrombosis and Thrombolysis

Volumn 13, Issue 1, 2002, Pages 41-47

  Kathiresan, S ^a   Shiomura, J ^b   Jang, I K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Anticoagulation; Argatroban; Direct thrombin inhibitor

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; DESULFATOHIRUDIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LEPIRUDIN; RECOMBINANT HIRUDIN; THROMBIN; THROMBIN INHIBITOR; WARFARIN; ANTITHROMBIN; PIPECOLIC ACID DERIVATIVE;

ANTICOAGULATION; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE MODEL; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG ISOLATION; DRUG MECHANISM; DRUG MONITORING; DRUG PREFERENCE; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INHIBITION KINETICS; KIDNEY FAILURE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION; THROMBOCYTOPENIA; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DRUG ANTAGONISM; METABOLISM; METHODOLOGY;

ANIMAL; ANTITHROMBINS; CLINICAL TRIALS; COMPARATIVE STUDY; HUMAN; KIDNEY FAILURE; PIPECOLIC ACIDS; THROMBIN; THROMBOCYTOPENIA; ANIMALS; HUMANS;

EID: 0035985007     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015368126304     Document Type: Review

References (35)

1. The thromboplastic action of cephalin
2. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
3. Thrombin signalling and protease-activated receptors
4. Antithrombotic therapy in acute coronary syndromes
5. New anticoagulants
6. Novastan (brand of argatroban): A small molecule, direct thrombin inhibitor
7. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and recombinant hirudin
8. No effect of clot age or thrombolysis on argatroban's inhibition of thrombin
9. Argatroban for the prevention and treatment of thromboembolism in heparin-induced thrombocytopenia
10. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects
11. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction
12. The preclinical and clinical pharmacology of Novastan (argatroban): A small molecule, direct thrombin inhibitor
13. Data on file
14. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805: The importance of stereostructure of its hydrophobic carboxamide portion
15. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator
16. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition
17. Persistent inhibition of arterial thrombosis by a 1-hour intravenous infusion of argatroban, a selective thrombin inhibitor
18. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion, and bleeding with recombinant tissue-type plasminogen activator in a canine preparation
19. A multi-center, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (tPA) in acute myocardial infarction: Myocardial infarction with novastan and tPA (MINT) study
20. Argatroban and alteplase in patients with acute myocardial infarction: The ARGAMI study
21. Argatroban versus heparin as adjuvant therapy to thrombolysis for acute myocardial infarction: Safety considerations - ARGAMI-2 study
22. Results from late breaking clinical trials session at ACC'97
23. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris
24. Reactivation of unstable angina after the discontinuation of heparin
25. Heparin induced thrombocytopenia: Diagnosis and contemporary antithrombin management
26. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia
27. Argatroban during percutaneous transluminal coronary angioplasty: Results of a dose-verification study
28. Results of a Phase 2/3 trial of argatroban anticoagulation during PTCA of patients with heparin-induced thrombocytopenia
29. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis
30. Effect of thrombin inhibition on patients with peripheral arterial obstructive disease: A multicenter clinical trial of argatroban
31. Clinical experience of argatroban for anticoagulation in cardiovascular surgery
32. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation
33. The international normalized ratio during concurrent warfarin and argatroban anticoagulation: Differential contributions of each agent and effects of the choice of thromboplastin used
34. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin
35. TACTICS (treat angina with aggrastat and determine cost of therapy with an invasive or conservative strategy) - Thrombolysis In Myocardial Infarction 18 investigators: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban